Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in male homosexuals in the Netherlands.

The efficacy of a heat-inactivated hepatitis B virus (HBV) vaccine, containing 3 micrograms-HBsAg, was studied among a group of 800 susceptible homosexual men. The trial was conducted randomized, placebo-controlled and double blind. At the trial end point (21.5 months) the attack-rate for all HBV infections together was 4.8% among vaccinees and 23.8% among the placebos (p less than 0.0001). Four months after the first injection 89% of the vaccinees had formed anti-HBs and this percentage declined only slightly during the follow-up period. Maximum titers were reached 5 months after the first vaccination. None of the vaccinees who responded to the vaccine with anti-HBs greater than or equal to 1 mIU/ml developed a HBsAg positive infection. The vaccine had no serious side-effects.
AuthorsR A Coutinho, P N Lelie, P Albrecht-van Lent, L Stoutjesdijk, J Huisman, H Kuipers, L J Schut, E E Reerink-Brongers, H W Reesink, W G van Aken
JournalDevelopments in biological standardization (Dev Biol Stand) Vol. 54 Pg. 287-92 ( 1983) ISSN: 0301-5149 [Print] SWITZERLAND
PMID6228469 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Hepatitis B Antibodies
  • Hepatitis B Vaccines
  • Viral Vaccines
  • Clinical Trials as Topic
  • Hepatitis B Antibodies (analysis)
  • Hepatitis B Vaccines
  • Homosexuality
  • Hot Temperature
  • Humans
  • Male
  • Netherlands
  • Viral Vaccines (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: